{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T10:30:22Z","timestamp":1788777022681,"version":"build-2803163510"},"reference-count":103,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T00:00:00Z","timestamp":1663113600000},"content-version":"vor","delay-in-days":256,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/R015767\/1"],"award-info":[{"award-number":["MR\/R015767\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","award":["MR\/T016515\/1"],"award-info":[{"award-number":["MR\/T016515\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000770","name":"University of Manchester","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000770","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,1]]},"abstract":"<jats:title>Summary<\/jats:title>\n               <jats:p>Inflammasomes and the interleukin (IL)-1 family of cytokines are key mediators of both inflammation and immunothrombosis. Inflammasomes are responsible for the release of the pro-inflammatory cytokines IL-1\u03b2 and IL-18, as well as releasing tissue factor (TF), a pivotal initiator of the extrinsic coagulation cascade. Uncontrolled production of inflammatory cytokines results in what is known as a \u201ccytokine storm\u201d leading to hyperinflammatory disease. Cytokine storms can complicate a variety of diseases and results in hypercytokinemia, coagulopathies, tissue damage, multiorgan failure, and death. Patients presenting with cytokine storm syndromes have a high mortality rate, driven in part by disseminated intravascular coagulation (DIC). While our knowledge on the factors propagating cytokine storms is increasing, how cytokine storm influences DIC remains unknown, and therefore treatments for diseases, where these aspects are a key feature are limited, with most targeting specific cytokines. Currently, no therapies target the immunothrombosis aspect of hyperinflammatory syndromes. Here we discuss how targeting the inflammasome and pyroptosis may be a novel therapeutic strategy for the treatment of hyperinflammation and its associated pathologies.<\/jats:p>","DOI":"10.1093\/discim\/kyac005","type":"journal-article","created":{"date-parts":[[2022,9,14]],"date-time":"2022-09-14T21:23:46Z","timestamp":1663190626000},"source":"Crossref","is-referenced-by-count":15,"title":["Looking into the IL-1 of the storm: are inflammasomes the link between immunothrombosis and hyperinflammation in cytokine storm syndromes?"],"prefix":"10.1093","volume":"1","author":[{"given":"Tara A","family":"Gleeson","sequence":"first","affiliation":[{"name":"Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester , Manchester , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester , Manchester , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"Nordling","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB , Stockholm 112 76 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Kaiser","sequence":"additional","affiliation":[{"name":"Swedish Orphan Biovitrum AB , Stockholm 112 76 , Sweden"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine B","family":"Lawrence","sequence":"additional","affiliation":[{"name":"Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester , Manchester , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester , Manchester , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Brough","sequence":"additional","affiliation":[{"name":"Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester , Manchester , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester , Manchester , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1108-3422","authenticated-orcid":false,"given":"Jack P","family":"Green","sequence":"additional","affiliation":[{"name":"Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester , Manchester , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester , Manchester , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stuart M","family":"Allan","sequence":"additional","affiliation":[{"name":"Division of Neuroscience and Experimental Psychology, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester , Manchester , UK"},{"name":"Geoffrey Jefferson Brain Research Centre, The Manchester Academic Health Science Centre, Northern Care Alliance NHS Group, University of Manchester , Manchester , UK"},{"name":"Lydia Becker Institute of Immunology and Inflammation, University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,9,14]]},"reference":[{"key":"2022101413464102000_CIT0001","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/ni.1863","article-title":"The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors","volume":"11","author":"Kawai","year":"2010","journal-title":"Nat Immunol"},{"key":"2022101413464102000_CIT0002","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1016\/j.cell.2014.04.007","article-title":"Mechanisms and functions of inflammasomes","volume":"157","author":"Lamkanfi","year":"2014","journal-title":"Cell"},{"key":"2022101413464102000_CIT0003","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.cell.2010.01.022","article-title":"Pattern recognition receptors and inflammation","volume":"140","author":"Takeuchi","year":"2010","journal-title":"Cell"},{"key":"2022101413464102000_CIT0004","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1038\/nrd.2016.39","article-title":"Resolution of inflammation: a new therapeutic frontier","volume":"15","author":"Fullerton","year":"2016","journal-title":"Nat Rev Drug Discov"},{"key":"2022101413464102000_CIT0005","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.cell.2010.02.029","article-title":"Nonresolving inflammation","volume":"140","author":"Nathan","year":"2010","journal-title":"Cell"},{"key":"2022101413464102000_CIT0006","doi-asserted-by":"crossref","first-page":"119","DOI":"10.3389\/fimmu.2019.00119","article-title":"The immunology of macrophage activation syndrome","volume":"10","author":"Crayne","year":"2019","journal-title":"Front Immunol"},{"key":"2022101413464102000_CIT0007","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1056\/NEJMra2026131","article-title":"Cytokine storm","volume":"383","author":"Fajgenbaum","year":"2020","journal-title":"N Engl J Med"},{"key":"2022101413464102000_CIT0008","doi-asserted-by":"crossref","first-page":"1446","DOI":"10.3389\/fimmu.2020.01446","article-title":"The COVID-19 cytokine storm; what we know so far","volume":"11","author":"Ragab","year":"2020","journal-title":"Front Immunol"},{"key":"2022101413464102000_CIT0009","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/j.semarthrit.2015.11.002","article-title":"Macrophage activation syndrome complicating adult onset Still\u2019s disease: a single center case series and comparison with literature","volume":"45","author":"Lenert","year":"2016","journal-title":"Semin Arthritis Rheum"},{"key":"2022101413464102000_CIT0010","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1182\/blood.2019000936","article-title":"Pediatric hemophagocytic lymphohistiocytosis","volume":"135","author":"Canna","year":"2020","journal-title":"Blood"},{"key":"2022101413464102000_CIT0011","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1007\/s00281-017-0639-8","article-title":"Cytokine storm and sepsis disease pathogenesis","volume":"39","author":"Chousterman","year":"2017","journal-title":"Semin Immunopathol"},{"key":"2022101413464102000_CIT0012","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s40425-018-0343-9","article-title":"Cytokine release syndrome","volume":"6","author":"Shimabukuro-Vornhagen","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"2022101413464102000_CIT0013","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1097\/PCC.0b013e3181a1ae08","article-title":"Secondary hemophagocytic lymphohistiocytosis and severe sepsis\/ systemic inflammatory response syndrome\/multiorgan dysfunction syndrome\/macrophage activation syndrome share common intermediate phenotypes on a spectrum of inflammation","volume":"10","author":"Castillo","year":"2009","journal-title":"Pediatr Crit Care Med"},{"key":"2022101413464102000_CIT0014","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2147\/OARRR.S151013","article-title":"Macrophage activation syndrome: early diagnosis is key","volume":"10","author":"Lerkvaleekul","year":"2018","journal-title":"Open Access Rheumatol"},{"key":"2022101413464102000_CIT0015","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1136\/thoraxjnl-2020-216243","article-title":"COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms","volume":"76","author":"Loo","year":"2021","journal-title":"Thorax"},{"key":"2022101413464102000_CIT0016","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1038\/nri3345","article-title":"Thrombosis as an intravascular effector of innate immunity","volume":"13","author":"Engelmann","year":"2013","journal-title":"Nat Rev Immunol"},{"key":"2022101413464102000_CIT0017","doi-asserted-by":"crossref","first-page":"1076029620943293","DOI":"10.1177\/1076029620943293","article-title":"COVID-19-associated coagulopathy: an exacerbated immunothrombosis response","volume":"26","author":"Jayarangaiah","year":"2020","journal-title":"Clin Appl Thromb Hemost"},{"key":"2022101413464102000_CIT0018","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1161\/01.CIR.0000131660.51520.9A","article-title":"Bidirectional relation between inflammation and coagulation","volume":"109","author":"Levi","year":"2004","journal-title":"Circulation"},{"key":"2022101413464102000_CIT0019","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/gene.2012.3","article-title":"Macrophage activation syndrome as part of systemic juvenile idiopathic arthritis: diagnosis, genetics, pathophysiology and treatment","volume":"13","author":"Ravelli","year":"2012","journal-title":"Genes Immun"},{"key":"2022101413464102000_CIT0020","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-gamma and interferon-gamma-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"2022101413464102000_CIT0021","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1016\/j.jaci.2017.07.021","article-title":"Neutralization of IFN-gamma reverts clinical and laboratory features in a mouse model of macrophage activation syndrome","volume":"141","author":"Prencipe","year":"2018","journal-title":"J Allergy Clin Immunol"},{"key":"2022101413464102000_CIT0022","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"key":"2022101413464102000_CIT0023","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J Clin Invest"},{"key":"2022101413464102000_CIT0024","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1182\/blood-2010-12-324533","article-title":"Perforin is a critical physiologic regulator of T-cell activation","volume":"118","author":"Lykens","year":"2011","journal-title":"Blood"},{"key":"2022101413464102000_CIT0025","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"key":"2022101413464102000_CIT0026","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"key":"2022101413464102000_CIT0027","doi-asserted-by":"crossref","first-page":"650295","DOI":"10.3389\/fphar.2021.650295","article-title":"Ruxolitinib, a JAK1\/2 inhibitor, ameliorates cytokine storm in experimental models of hyperinflammation syndrome","volume":"12","author":"Huarte","year":"2021","journal-title":"Front Pharmacol"},{"key":"2022101413464102000_CIT0028","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2020.11.025","article-title":"Synergism of TNF-alpha and IFN-gamma triggers inflammatory cell death, tissue damage, and mortality in SARS-CoV-2 infection and cytokine shock syndromes","volume":"184","author":"Karki","year":"2021","journal-title":"Cell"},{"key":"2022101413464102000_CIT0029","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1159\/000338179","article-title":"Critical imbalance of TNF-alpha and soluble TNF receptor 1 in a patient with macrophage activation syndrome: potential implications for diagnostics and treatment","volume":"128","author":"Flammiger","year":"2012","journal-title":"Acta Haematol"},{"key":"2022101413464102000_CIT0030","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/acr.23277","article-title":"Effect of biologic therapy on clinical and laboratory features of macrophage activation syndrome associated with systemic juvenile idiopathic arthritis","volume":"70","author":"Schulert","year":"2018","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2022101413464102000_CIT0031","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.immuni.2013.11.010","article-title":"The interleukin-1 family: back to the future","volume":"39","author":"Garlanda","year":"2013","journal-title":"Immunity"},{"key":"2022101413464102000_CIT0032","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"2022101413464102000_CIT0033","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1038\/s41392-021-00650-z","article-title":"Inflammasomes as therapeutic targets in human diseases","volume":"6","author":"Li","year":"2021","journal-title":"Signal Transduct Target Ther"},{"key":"2022101413464102000_CIT0034","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/s41586-021-03218-7","article-title":"NINJ1 mediates plasma membrane rupture during lytic cell death","volume":"591","author":"Kayagaki","year":"2021","journal-title":"Nature"},{"key":"2022101413464102000_CIT0035","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1038\/nri.2016.58","article-title":"Inflammasomes: mechanism of assembly, regulation and signalling","volume":"16","author":"Broz","year":"2016","journal-title":"Nat Rev Immunol"},{"key":"2022101413464102000_CIT0036","doi-asserted-by":"crossref","first-page":"e20190314","DOI":"10.1084\/jem.20190314","article-title":"Inflammasome signaling and regulation of interleukin-1 family cytokines","volume":"217","author":"Chan","year":"2020","journal-title":"J Exp Med"},{"key":"2022101413464102000_CIT0037","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/S0140-6736(20)30628-0","article-title":"COVID-19: consider cytokine storm syndromes and immunosuppression","volume":"395","author":"Mehta","year":"2020","journal-title":"Lancet"},{"key":"2022101413464102000_CIT0038","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American college of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"2022101413464102000_CIT0039","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1007\/s00296-016-3545-9","article-title":"Macrophage activation syndrome in children with systemic juvenile idiopathic arthritis and systemic lupus erythematosus","volume":"36","author":"Aytac","year":"2016","journal-title":"Rheumatol Int"},{"key":"2022101413464102000_CIT0040","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1093\/rheumatology\/keq218","article-title":"Successful treatment of severe paediatric rheumatic disease-associated macrophage activation syndrome with interleukin-1 inhibition following conventional immunosuppressive therapy: case series with 12 patients","volume":"50","author":"Miettunen","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"2022101413464102000_CIT0041","doi-asserted-by":"crossref","first-page":"398","DOI":"10.3899\/jrheum.210563","article-title":"Anakinra in Patients with systemic juvenile idiopathic arthritis: long-term safety from the pharmachild registry","volume":"49","author":"Giancane","year":"2022","journal-title":"J Rheumatol"},{"key":"2022101413464102000_CIT0042","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1084\/jem.20050473","article-title":"Role of interleukin-1 (IL-1) in the pathogenesis of systemic onset juvenile idiopathic arthritis and clinical response to IL-1 blockade","volume":"201","author":"Pascual","year":"2005","journal-title":"J Exp Med"},{"key":"2022101413464102000_CIT0043","doi-asserted-by":"crossref","first-page":"4415","DOI":"10.1002\/pmic.201000298","article-title":"Plasma profiles in active systemic juvenile idiopathic arthritis: biomarkers and biological implications","volume":"10","author":"Ling","year":"2010","journal-title":"Proteomics"},{"key":"2022101413464102000_CIT0044","doi-asserted-by":"crossref","first-page":"e147593","DOI":"10.1172\/jci.insight.147593","article-title":"IFN-gamma is essential for alveolar macrophage-driven pulmonary inflammation in macrophage activation syndrome","volume":"6","author":"Gao","year":"2021","journal-title":"JCI Insight"},{"key":"2022101413464102000_CIT0045","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/s41577-021-00588-x","article-title":"Inflammasome activation at the crux of severe COVID-19","volume":"21","author":"Vora","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"2022101413464102000_CIT0046","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.1038\/s41591-020-1051-9","article-title":"An inflammatory cytokine signature predicts COVID-19 severity and survival","volume":"26","author":"Del Valle","year":"2020","journal-title":"Nat Med"},{"key":"2022101413464102000_CIT0047","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1038\/s41420-021-00428-w","article-title":"SARS-CoV-2 engages inflammasome and pyroptosis in human primary monocytes","volume":"7","author":"Ferreira","year":"2021","journal-title":"Cell Death Discov"},{"key":"2022101413464102000_CIT0048","doi-asserted-by":"crossref","first-page":"e20201707","DOI":"10.1084\/jem.20201707","article-title":"Inflammasomes are activated in response to SARS-CoV-2 infection and are associated with COVID-19 severity in patients","volume":"218","author":"Rodrigues","year":"2021","journal-title":"J Exp Med"},{"key":"2022101413464102000_CIT0049","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-022-04802-1","article-title":"Inflammasome activation in infected macrophages drives COVID-19 pathology","volume":"606","author":"Sefik","year":"2022","journal-title":"Nature"},{"key":"2022101413464102000_CIT0050","doi-asserted-by":"crossref","first-page":"100393","DOI":"10.1016\/j.lanepe.2022.100393","article-title":"Hyper inflammatory syndrome following COVID-19 mRNA vaccine in children: a national post-authorization pharmacovigilance study","volume":"17","author":"Ouldali","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"2022101413464102000_CIT0051","doi-asserted-by":"crossref","first-page":"532","DOI":"10.1038\/s41590-022-01160-y","article-title":"IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines","volume":"23","author":"Tahtinen","year":"2022","journal-title":"Nat Immunol"},{"key":"2022101413464102000_CIT0052","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1001\/jama.2021.9508","article-title":"Effect of Canakinumab vs Placebo on survival without invasive mechanical ventilation in patients hospitalized with severe COVID-19: a randomized clinical trial","volume":"326","author":"Caricchio","year":"2021","journal-title":"JAMA"},{"key":"2022101413464102000_CIT0053","doi-asserted-by":"crossref","first-page":"21775","DOI":"10.1038\/s41598-020-78492-y","article-title":"Blockage of interleukin-1beta with canakinumab in patients with Covid-19","volume":"10","author":"Landi","year":"2020","journal-title":"Sci Rep"},{"key":"2022101413464102000_CIT0054","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1038\/s41591-021-01499-z","article-title":"Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: a double-blind, randomized controlled phase 3 trial","volume":"27","author":"Kyriazopoulou","year":"2021","journal-title":"Nat Med"},{"key":"2022101413464102000_CIT0055","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s12969-020-00450-9","article-title":"Successful treatment of refractory hyperferritinemic syndromes with canakinumab: a report of two cases","volume":"18","author":"Papa","year":"2020","journal-title":"Pediatr Rheumatol Online J"},{"key":"2022101413464102000_CIT0056","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1136\/annrheumdis-2018-213150","article-title":"Canakinumab in patients with systemic juvenile idiopathic arthritis and active systemic features: results from the 5-year long-term extension of the phase III pivotal trials","volume":"77","author":"Ruperto","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2022101413464102000_CIT0057","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/art.39407","article-title":"Rate and clinical presentation of macrophage activation syndrome in patients with systemic juvenile idiopathic arthritis treated with canakinumab","volume":"68","author":"Grom","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"2022101413464102000_CIT0058","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1002\/art.38699","article-title":"Randomized, double-blind, placebo-controlled trial of the efficacy and safety of rilonacept in the treatment of systemic juvenile idiopathic arthritis","volume":"66","author":"Ilowite","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"2022101413464102000_CIT0059","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3810\/pgm.2010.09.2209","article-title":"Inflammasome-mediated autoinflammatory disorders","volume":"122","author":"Wilson","year":"2010","journal-title":"Postgrad Med"},{"key":"2022101413464102000_CIT0060","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1002\/JLB.3MIR0919-191R","article-title":"Inflammasomes in the pathophysiology of autoinflammatory syndromes","volume":"107","author":"Tartey","year":"2020","journal-title":"J Leukoc Biol"},{"key":"2022101413464102000_CIT0061","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.jpeds.2004.12.016","article-title":"Preliminary diagnostic guidelines for macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"146","author":"Ravelli","year":"2005","journal-title":"J Pediatr"},{"key":"2022101413464102000_CIT0062","doi-asserted-by":"crossref","first-page":"1442","DOI":"10.1182\/blood-2017-12-820852","article-title":"Interleukin-18 diagnostically distinguishes and pathogenically promotes human and murine macrophage activation syndrome","volume":"131","author":"Weiss","year":"2018","journal-title":"Blood"},{"key":"2022101413464102000_CIT0063","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s41927-019-0053-z","article-title":"Comparative study of interleukin-18 (IL-18) serum levels in adult onset Still\u2019s disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity","volume":"3","author":"Kudela","year":"2019","journal-title":"BMC Rheumatol"},{"key":"2022101413464102000_CIT0064","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1093\/rheumatology\/keq133","article-title":"Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis","volume":"49","author":"Shimizu","year":"2010","journal-title":"Rheumatology (Oxford)"},{"key":"2022101413464102000_CIT0065","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1093\/rheumatology\/kez282","article-title":"IL-18 as a biomarker linking systemic juvenile idiopathic arthritis and macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022101413464102000_CIT0066","doi-asserted-by":"crossref","first-page":"3483","DOI":"10.1182\/blood-2005-05-1980","article-title":"Severe imbalance of IL-18\/IL-18BP in patients with secondary hemophagocytic syndrome","volume":"106","author":"Mazodier","year":"2005","journal-title":"Blood"},{"key":"2022101413464102000_CIT0067","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1038\/ng.3089","article-title":"An activating NLRC4 inflammasome mutation causes autoinflammation with recurrent macrophage activation syndrome","volume":"46","author":"Canna","year":"2014","journal-title":"Nat Genet"},{"key":"2022101413464102000_CIT0068","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.1016\/j.jaci.2016.10.022","article-title":"Life-threatening NLRC4-associated hyperinflammation successfully treated with IL-18 inhibition","volume":"139","author":"Canna","year":"2017","journal-title":"J Allergy Clin Immunol"},{"key":"2022101413464102000_CIT0069","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.virol.2012.09.012","article-title":"Anti-viral CD8 T cells and the cytokines that they love","volume":"435","author":"Cox","year":"2013","journal-title":"Virology"},{"key":"2022101413464102000_CIT0070","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1038\/ni.2195","article-title":"NLRC4 inflammasomes in dendritic cells regulate noncognate effector function by memory CD8(+) T cells","volume":"13","author":"Kupz","year":"2012","journal-title":"Nat Immunol"},{"key":"2022101413464102000_CIT0071","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/1529-0131(200103)44:3<550::AID-ANR103>3.0.CO;2-5","article-title":"Levels of interleukin-18 and its binding inhibitors in the blood circulation of patients with adult-onset Still\u2019s disease","volume":"44","author":"Kawashima","year":"2001","journal-title":"Arthritis Rheum"},{"key":"2022101413464102000_CIT0072","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1074-7613(00)80013-8","article-title":"Interleukin-18 binding protein: a novel modulator of the Th1 cytokine response","volume":"10","author":"Novick","year":"1999","journal-title":"Immunity"},{"key":"2022101413464102000_CIT0073","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1182\/blood-2017-06-789552","article-title":"Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice","volume":"131","author":"Girard-Guyonvarc\u2019h","year":"2018","journal-title":"Blood"},{"key":"2022101413464102000_CIT0074","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1093\/rheumatology\/kez284","article-title":"IL-18 as therapeutic target in a patient with resistant systemic juvenile idiopathic arthritis and recurrent macrophage activation syndrome","volume":"59","author":"Yasin","year":"2020","journal-title":"Rheumatology (Oxford)"},{"key":"2022101413464102000_CIT0075","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1073\/pnas.97.3.1190","article-title":"Structural requirements of six naturally occurring isoforms of the IL-18 binding protein to inhibit IL-18","volume":"97","author":"Kim","year":"2000","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022101413464102000_CIT0076","doi-asserted-by":"crossref","first-page":"2367","DOI":"10.1182\/blood-2009-05-199208","article-title":"Coagulation and innate immune responses: can we view them separately?","volume":"114","author":"Delvaeye","year":"2009","journal-title":"Blood"},{"key":"2022101413464102000_CIT0077","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1056\/NEJM199908193410807","article-title":"Disseminated intravascular coagulation","volume":"341","author":"Levi","year":"1999","journal-title":"N Engl J Med"},{"key":"2022101413464102000_CIT0078","doi-asserted-by":"crossref","first-page":"1392","DOI":"10.1161\/CIRCRESAHA.116.306853","article-title":"Cross talk pathways between coagulation and inflammation","volume":"118","author":"Foley","year":"2016","journal-title":"Circ Res"},{"key":"2022101413464102000_CIT0079","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1038\/ni.1703","article-title":"The inflammasome: a caspase-1-activation platform that regulates immune responses and disease pathogenesis","volume":"10","author":"Franchi","year":"2009","journal-title":"Nat Immunol"},{"key":"2022101413464102000_CIT0080","doi-asserted-by":"crossref","first-page":"326","DOI":"10.3109\/10409238.2015.1050550","article-title":"How it all starts: initiation of the clotting cascade","volume":"50","author":"Smith","year":"2015","journal-title":"Crit Rev Biochem Mol Biol"},{"key":"2022101413464102000_CIT0081","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1161\/01.ATV.0000130465.23430.74","article-title":"Role of tissue factor in hemostasis, thrombosis, and vascular development","volume":"24","author":"Mackman","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"2022101413464102000_CIT0082","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.immuni.2019.04.003","article-title":"Inflammasome activation triggers blood clotting and host death through pyroptosis","volume":"50","author":"Wu","year":"2019","journal-title":"Immunity"},{"key":"2022101413464102000_CIT0083","doi-asserted-by":"crossref","first-page":"2619","DOI":"10.1182\/bloodadvances.2020003041","article-title":"Inflammasome activation promotes venous thrombosis through pyroptosis","volume":"5","author":"Zhang","year":"2021","journal-title":"Blood Adv"},{"key":"2022101413464102000_CIT0084","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1073\/pnas.1620458114","article-title":"Activation of NLRP3 inflammasome complex potentiates venous thrombosis in response to hypoxia","volume":"114","author":"Gupta","year":"2017","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022101413464102000_CIT0085","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1172\/JCI79329","article-title":"Caspase-1-mediated pathway promotes generation of thromboinflammatory microparticles","volume":"125","author":"Rothmeier","year":"2015","journal-title":"J Clin Invest"},{"key":"2022101413464102000_CIT0086","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/SHK.0000000000000509","article-title":"Circulating microparticles, blood cells, and endothelium induce procoagulant activity in sepsis through phosphatidylserine exposure","volume":"45","author":"Zhang","year":"2016","journal-title":"Shock"},{"key":"2022101413464102000_CIT0087","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.immuni.2019.11.005","article-title":"Bacterial endotoxin activates the coagulation cascade through gasdermin D-dependent phosphatidylserine exposure","volume":"51","author":"Yang","year":"2019","journal-title":"Immunity"},{"key":"2022101413464102000_CIT0088","doi-asserted-by":"crossref","first-page":"5271","DOI":"10.1182\/blood-2008-01-078204","article-title":"The vessel wall and its interactions","volume":"111","author":"Wagner","year":"2008","journal-title":"Blood"},{"key":"2022101413464102000_CIT0089","doi-asserted-by":"crossref","first-page":"15880","DOI":"10.1073\/pnas.1005743107","article-title":"Extracellular DNA traps promote thrombosis","volume":"107","author":"Fuchs","year":"2010","journal-title":"Proc Natl Acad Sci USA"},{"key":"2022101413464102000_CIT0090","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1172\/JCI92880","article-title":"Factor XII and uPAR upregulate neutrophil functions to influence wound healing","volume":"128","author":"Stavrou","year":"2018","journal-title":"J Clin Invest"},{"key":"2022101413464102000_CIT0091","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1093\/eurheartj\/ehv007","article-title":"Expression of functional tissue factor by neutrophil extracellular traps in culprit artery of acute myocardial infarction","volume":"36","author":"Stakos","year":"2015","journal-title":"Eur Heart J"},{"key":"2022101413464102000_CIT0092","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1182\/bloodadvances.2020003377","article-title":"Neutrophil extracellular traps and inflammasomes cooperatively promote venous thrombosis in mice","volume":"5","author":"Campos","year":"2021","journal-title":"Blood Adv"},{"key":"2022101413464102000_CIT0093","doi-asserted-by":"crossref","first-page":"eaar6689","DOI":"10.1126\/sciimmunol.aar6689","article-title":"Gasdermin D plays a vital role in the generation of neutrophil extracellular traps","volume":"3","author":"Sollberger","year":"2018","journal-title":"Sci Immunol"},{"key":"2022101413464102000_CIT0094","doi-asserted-by":"crossref","first-page":"eaar6676","DOI":"10.1126\/sciimmunol.aar6676","article-title":"Noncanonical inflammasome signaling elicits gasdermin D-dependent neutrophil extracellular traps","volume":"3","author":"Chen","year":"2018","journal-title":"Sci Immunol"},{"key":"2022101413464102000_CIT0095","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1084\/jem.20172222","article-title":"Caspase-1 self-cleavage is an intrinsic mechanism to terminate inflammasome activity","volume":"215","author":"Boucher","year":"2018","journal-title":"J Exp Med"},{"key":"2022101413464102000_CIT0096","doi-asserted-by":"crossref","first-page":"e103397","DOI":"10.15252\/embj.2019103397","article-title":"Beyond inflammasomes: emerging function of gasdermins during apoptosis and NETosis","volume":"39","author":"Chen","year":"2020","journal-title":"EMBO J"},{"key":"2022101413464102000_CIT0097","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1038\/s41584-018-0124-3","article-title":"Gasdermin D opens the way for NETs","volume":"14","author":"Spel","year":"2018","journal-title":"Nat Rev Rheumatol"},{"key":"2022101413464102000_CIT0098","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1016\/j.bbrc.2016.12.161","article-title":"The NLRP3 inflammasome and bruton\u2019s tyrosine kinase in platelets co-regulate platelet activation, aggregation, and in vitro thrombus formation","volume":"483","author":"Murthy","year":"2017","journal-title":"Biochem Biophys Res Commun"},{"key":"2022101413464102000_CIT0099","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.3324\/haematol.2018.191700","article-title":"NLRP3 regulates platelet integrin alphaIIbbeta3 outside-in signaling, hemostasis and arterial thrombosis","volume":"103","author":"Qiao","year":"2018","journal-title":"Haematologica"},{"key":"2022101413464102000_CIT0100","doi-asserted-by":"crossref","first-page":"107615","DOI":"10.1016\/j.celrep.2020.107615","article-title":"Platelets fuel the inflammasome activation of innate immune cells","volume":"31","author":"Rolfes","year":"2020","journal-title":"Cell Rep"},{"key":"2022101413464102000_CIT0101","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.immuni.2019.03.003","article-title":"The coagulation and immune systems are directly linked through the activation of interleukin-1alpha by thrombin","volume":"50","author":"Burzynski","year":"2019","journal-title":"Immunity"},{"key":"2022101413464102000_CIT0102","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1083\/jcb.201410052","article-title":"IL-1alpha induces thrombopoiesis through megakaryocyte rupture in response to acute platelet needs","volume":"209","author":"Nishimura","year":"2015","journal-title":"J Cell Biol"},{"key":"2022101413464102000_CIT0103","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tips.2022.04.003","article-title":"NLRP3 and pyroptosis blockers for treating inflammatory diseases","volume":"43","author":"Coll","year":"2022","journal-title":"Trends Pharmacol Sci"}],"container-title":["Discovery Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/discovimmunology\/advance-article-pdf\/doi\/10.1093\/discim\/kyac005\/45851350\/kyac005.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/discovimmunology\/article-pdf\/1\/1\/kyac005\/46527100\/kyac005.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/discovimmunology\/article-pdf\/1\/1\/kyac005\/46527100\/kyac005.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,14]],"date-time":"2022-10-14T21:18:35Z","timestamp":1665782315000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/discovimmunology\/article\/doi\/10.1093\/discim\/kyac005\/6698699"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,1]]},"references-count":103,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/discim\/kyac005","relation":{},"ISSN":["2754-2483"],"issn-type":[{"value":"2754-2483","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,1]]},"published":{"date-parts":[[2022,1,1]]},"article-number":"kyac005"}}